NovAccess Global, Inc. Names Neil Laird, Chief Financial Officer
NovAccess Global (OTC PINK:XSNX) has appointed Neil Laird as the new Chief Financial Officer, following the contributions of former CFO Mike Yukich. Laird brings extensive experience in finance, having previously held CFO roles at Mobileum Inc. and SumTotal Systems. NovAccess is focused on developing innovative cancer diagnostics and therapeutics, including a cancer vaccine therapy targeting glioblastoma multiforme, which has a challenging prognosis. The company aims to enhance patient immune response against tumors, potentially improving outcomes for cancer patients.
- Appointment of Neil Laird as CFO brings experienced financial leadership.
- Ongoing development of a unique cancer vaccine therapy targeting glioblastoma multiforme, showcasing potential for significant therapeutic impact.
- None.
CLEVELAND, OH / ACCESSWIRE / December 8, 2021 / NovAccess Global, Inc. (OTC PINK:XSNX) welcomes new Chief Financial Officer (CFO), Neil Laird.
"I am pleased to welcome Neil Laird to the management team," said Dr. Dwain Irvin, Chief Executive Officer, NovAccess Global.
Neil J. Laird is an experienced financial executive who works with emerging companies to provide accounting and finance-related services. Since 2017, he has worked with several technology and other companies as a consultant. Before that, he was the Chief Financial Officer of Mobileum Inc., a private company providing roaming and other solutions to the telecommunications industry. Prior to this, he was Chief Financial Officer at SumTotal Systems, a provider of enterprise learning management systems and before that, Chief Financial Officer at ADAC Laboratories, a provider of nuclear medicine and PET systems. Both were publicly traded companies. He also held senior management positions at Coherent Medical Lasers and Measurex Corporation. Mr. Laird has an MA from the University of Cambridge and qualified as a UK chartered accountant.
We thank ex-Chief Financial Officer, Mike Yukich who came out of retirement and helped NovAccess Global spin-off from the parent company Innovest Global.
About NovAccess Global
NovAccess Global is a biomedical company accelerating novel cancer diagnostics and therapeutics. Our goal is to discover, develop and bring to market novel and innovative medicine and medical devices to improve the quality of care for cancer and neurological patients.
NovAccess Global is currently developing a cancer vaccine therapy that enhances the patient's immune response against brain tumors. Our company has a novel immunotherapeutic approach to treat brain tumor patients with glioblastoma multiforme, the most common adult brain tumor with a 15-month median survival after diagnosis. Our patented technology is designed to combine a dendritic cell-based immunotherapeutic approach with a unique combination of Toll-like receptor (TLR) adjuvants, TLR-AD1, to help promote an enhanced immune response against the patient's tumor. Our platform technology focuses on enhancing the patient's immune cells to fight their unique cancer by utilizing the antigens specific to the patient's tumor. The company owns a cancer vaccine, which is a medication that stimulates or restores the immune system's ability to fight existing cancer by strengthening the body's natural defenses against the cancer cells. It is a meaningful technology which could significantly improve the quality of life and prognosis for the many people who suffer from brain tumors. For more information, please visit novaccessglobal.com.
Forward-Looking Statement
This press release and its attachments contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may," "future," "plan" or "planned," "will" or "should," "expected," "anticipates," "draft," "eventually" or "projected." You are cautioned that such statements are subject to a multitude or risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in the company's disclosures or filings with the Securities Exchange Commission and/or OTC Markets, Inc. You are further cautioned that penny stocks and stocks of smaller companies like NovAccess, Inc. are inherently volatile and risky and that no investor should buy this stock unless they can afford the loss of their entire investment. The company disclaims any obligation to update any forward-looking statements to reflect events or circumstances after the date thereof.
Investor Relations Contact:
Satya Chillara
Darrow Associates
(510) 396 -2776
schillara@darrowassociates.com
SOURCE: NovAccess Global Inc.
View source version on accesswire.com:
https://www.accesswire.com/676437/NovAccess-Global-Inc-Names-Neil-Laird-Chief-Financial-Officer
FAQ
Who has been appointed as the new CFO of NovAccess Global (XSNX)?
What is the focus of NovAccess Global (XSNX) in cancer treatment?
What experience does Neil Laird bring to NovAccess Global (XSNX)?
What is the prognosis for glioblastoma multiforme patients that NovAccess Global (XSNX) is targeting?
Who did Neil Laird replace as CFO at NovAccess Global (XSNX)?
